April 17, 2026: Gliomic announces publication by co-founders Bill Kaelin, M.D. and Sam McBrayer, Ph.D. of scientific pre-print demonstrating precise mechanism-of-action of DHODH inhibition in IDH mutant tumor cells, highlighting strong in vivo efficacy and tolerability of Gliomic’s lead candidate.
https://www.biorxiv.org/content/10.64898/2026.04.14.715350v1